Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will present new data from multiple preclinical and clinical programs at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting. The TPD Summit will be held October 30–November 2 in Boston, Massachusetts, and CTOS will be held November 1–4 in Dublin, Ireland.
6th Annual Targeted Protein Degradation Summit
Foghorn will participate in multiple sessions, including a keynote presentation by Steve Bellon, Foghorn’s Chief Scientific Officer, where data from its selective EP300 and CBP degrader programs will be presented. Danette Daniels, Foghorn’s Vice President, Protein Degradation Platform, will provide the conference’s opening remarks as the Chair.
Presentation Details
Title: Advancement of Degraders Targeting Key Chromatin Regulators Involved in Disease/Oncology
Presenter: Steve Bellon, Chief Scientific Officer, Foghorn Therapeutics
Session: Keynote Plenary Session
Date: October 31, 2023
Time: 9:30 a.m. ET
Title: Lay of the Land – What Does the Next 3 Years of TPD Drug Discovery & Development Look Like?
Presenter: Laura La Bonte, Senior Director, Biology & Research Portfolio Strategy, Foghorn Therapeutics
Session: Clinical Development
Date: October 31, 2023
Time: 2:30 p.m. ET
Connective Tissue Oncology Society Annual Meeting
Presentation Details
Title: Preliminary results from a Phase 1 study of FHD-609, a bromodomain-containing protein 9 degrader, in patients with advanced synovial sarcoma or SMARCB1-loss tumors
Presenter: J. Andrew Livington, M.D., M.S., MD Anderson Cancer Center
Session: Session 4, Paper 25
Session date and time: November 2, 2023, 16:00-17:30 WET
Title: Pharmacodynamic and mechanistic impacts of FHD-609, A BRD9 degrader, in a Phase 1 study in patients with advanced synovial sarcoma or SMARCB1-loss tumors
Session date and time: November 2, 2023, 17:30-18:30 WET
Presenter: Mike Collins, Senior Scientist, Foghorn Therapeutics
